

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>BAMFORD PASCAL</u> (Last) (First) (Middle) <u>C/O AKOYA BIOSCIENCES, INC.</u> <u>100 CAMPUS DRIVE, 6TH FLOOR</u> (Street) <u>MARLBOROUGH MA</u> <u>01752</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/29/2024</u>	3. Issuer Name and Ticker or Trading Symbol <u>Akoya Biosciences, Inc. [AKYA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Clinical Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	82,758	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Employee Stock Option (Right to Buy)	(1)	11/12/2031	Common Stock	150,000	13.34	D
Employee Stock Option (Right to Buy)	(2)	02/23/2033	Common Stock	25,000	12.3	D
Employee Stock Option (Right to Buy)	(3)	05/18/2033	Common Stock	15,000	5.96	D
Employee Stock Option (Right to Buy)	(4)	02/22/2034	Common Stock	50,000	5.35	D

Explanation of Responses:

- The option, representing a right to purchase a total of 150,000 shares, became exercisable as follows: one-fourth of the shares vested on September 20, 2022, and the remaining shares vested in 36 equal monthly installments beginning on October 20, 2022.
- The option, representing a right to purchase a total of 25,000 shares, became exercisable as follows: one-fourth of the shares vested on February 23, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on March 23, 2024, subject to reporting person's continuous employment.
- The option, representing a right to purchase a total of 15,000 shares, became exercisable as follows: one-fourth of the shares vested on May 18, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on June 18, 2024, subject to reporting person's continuous employment.
- The option, representing a right to purchase a total of 50,000 shares, becomes exercisable as follows: one-fourth of the shares vests on February 22, 2025 with the remaining shares vesting in 36 equal monthly installments beginning on March 22, 2025, subject to reporting person's continuous employment.

/s/ Pascal Bamford by Brian McKelligon, 09/03/2024
Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Brian McKelligon and Branden Steinberg as the undersigned

- (1) with respect to the equity securities of Akoya Biosciences, Inc., a Delaware corporation (the "Company"), prepare, execute, acknowledge
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his or her discretion on information provided
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section

The undersigned hereby gives and grants the foregoing attorneys-in-fact, and each of them, full power and authority to do and perform any and all acts that the undersigned is authorized to do and perform by this Power of Attorney. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports (including Forms 3, 4 and 5) under the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of September, 2024.

/s/ Pascal Bamford

Pascal Bamford